Industry-leading real-time PCR, imaging, and nucleic acid extraction tools.
A Strategic Whitepaper on Industry Transformation and Future Roadmaps
The global In-Vitro Diagnostics (IVD) market is undergoing a seismic shift. Point-of-Care Testing (POCT) has emerged as the fastest-growing segment, transitioning from simple glucose strips to sophisticated Molecular POCT (mPOCT) systems. Currently, the market is valued at over $45 billion, with a projected CAGR of 10.5% through 2030. China has solidified its position as a global manufacturing powerhouse, not just in volume, but in high-tech innovation, offering clinical-grade accuracy in portable formats.
The "Information Gain" in modern SEO and diagnostics lies in integration. We are seeing three major trends:
Miniaturizing complex laboratory processes into single-use cartridges, reducing reagent waste and human error.
Moving beyond raw data to provide diagnostic insights, using machine learning to filter noise in fluorescence detection.
Real-time data synchronization with Hospital Information Systems (HIS) and Cloud-based epidemiological tracking.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
Defining the next decade of decentralized healthcare
BioX Medical’s product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Detection of 10+ pathogens in a single 30-minute run.
Utilizing gene-editing tools for ultra-sensitive, amplification-free detection.
Clinical-grade PCR performance in a consumer-friendly, hand-held device.
Serving Europe, North America, Asia-Pacific, the Middle East, and Africa.
Fast-track diagnosis in emergency rooms and ICUs, enabling immediate treatment decisions for sepsis or respiratory infections.
On-site detection of canine distemper, parvovirus, and feline leukemia using specialized 4-channel imaging fluorescence systems.
High-throughput automated DNA/RNA extraction and gel imaging systems for genomic research and drug discovery.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, BioX Medical continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
Precision equipment for diverse diagnostic environments.
Committed to advancing modern laboratory technologies, BioX Medical focuses on delivering reliable, scalable, and innovative diagnostic systems that support disease detection, genetic analysis, clinical research, and precision healthcare initiatives. Through continuous technological advancement and customer-oriented development, the company strives to contribute to the global evolution of molecular diagnostics and laboratory medicine.
BioX Medical
